
Tobias Bald
@doc_bald
I am a tumor biologist and immunologist studying the phenotypic plasticity of cells in the tumor microenvironment.
ID: 986463729893044224
http://www.baldlab.com 18-04-2018 04:37:35
109 Tweet
456 Followers
572 Following


đš JOB ALERTS đš We are hiring! Fully funded PhD and Postdoc positions available! Come work with us! Schultze Lab Great team, infrastructure and scientific environment! đïž Apply until April 30!

LAMP-Seq with 1-enzyme protocol out today go.nature.com/3y85GfE, grateful to colleagues @ Bonn&Boston! Kerstin Ludwig Ricarda Schmithausen David Li @ronhollstein MikoĆaj SĆabicki Nina Ishorst Lara Hochfeld Eva Beins @InesKalt @MaxSticks7 @ern_esth Jacob Borrajo Jonathan Strecker Michael Hölzel Feng Zhang


đCongratulations to Tobias Bald for recieving the Lisec-Artz Prize, together with Sebastian Kobold! Well deserved! Rheinische Friedrich-Wilhelms-UniversitĂ€t Bonn Uniklinik Bonn IEO_BaldLab

We are happy to share the most recent publication from our Institute by PhD student @InesKalt describing Hip Kinases as a target of the FDA approved cancer drug Abemaciclib. Read the full article in Nature Communications here: nature.com/articles/s4146âŠ


đ„łAttention science enthusiastsđ„łWe are excited to announce the launch of our new IEO website. Check it out to find out more about our research and spread the word đieo.uni-bonn.de ImmunoSensation @HCM_Bonn Uniklinik Bonn Rheinische Friedrich-Wilhelms-UniversitĂ€t Bonn

CRP as biomarker to predict responses to immune checkpoint inhibitors in patients with metastatic renal cancer. Great potential for the clinic as simple and cost-effective. Congrats to Niklas KlĂŒmper Uniklinik Bonn and collaborators. onlinelibrary.wiley.com/doi/full/10.10âŠ

New paper published by KlĂŒmper et al. about CRP as a biomarker in metastatic renal cancer. Congratulations to all collaboratorsđNiklas KlĂŒmper

We are excited to welcome Prof Tobias Bald IEO_BaldLab Rheinische Friedrich-Wilhelms-UniversitĂ€t Bonn & Prof Marco Herold WEHI (Walter and Eliza Hall Institute) UniMelb MDHS as new PIs to our program! DFG funding DFG public | @[email protected] for their project investigating CD155-CD226 interactions for T cell functionality in cancer has been approved đ„ł

Longitudinal CRP kinetics (CRP Flare đ„) predicts immunotherapy response within the first month in NSCLC! Great tool for therapy monitoring and as an integral biomarker for biomarker-directed study design Niklas KlĂŒmper Tobias Bald @IEO_BaldLab IEO_Bonn ImmunoSensation Rheinische Friedrich-Wilhelms-UniversitĂ€t Bonn

Longitudinal CRP kinetics (CRP Flare :fire:) predicts immunotherapy response within the first month in NSCLC! Great tool for therapy monitoring and as an integral biomarker for biomarker-directed study design Niklas KlĂŒmper Tobias Bald @IEO_BaldLab IEO_Bonn ImmunoSensation Rheinische Friedrich-Wilhelms-UniversitĂ€t Bonn

Thanks to all participants of our retreat Rheinische Friedrich-Wilhelms-UniversitÀt Bonn University of Melbourne for interesting & inspiring talks, networking and great interactions - it was fun to meet in person again!


After 5 days of #science and networking, the ImmunoSensation2 SummerSchool "#Immunology at scales" comes to an end. We hope everyone had a great time at Schwanenwerda #Abendsonne đ Also want to be a #PhD #Student ImmunoSensation? đimmunosensation.de/opportunities/âŠ


Well done Fenna!!! You are a fantastic PhD student keep up with the good science! Thanks Rheinische Friedrich-Wilhelms-UniversitÀt Bonn, University of Melbourne and Bonn & Melbourne Research and Graduate School for this great Retreat!

Happy to share our work: Integrating On-Treatment Modified Glasgow Prognostic Score and Imaging to Predict Response and Outcomes in Metastatic Renal Cell Carcinoma JAMA Oncology. See our tweetorial and the terrific editorial by Georges Gebrael Gliceida Galarza, MD Neeraj Agarwal, MD, FASCO UroToday.com 1/7

Excellent presentation by Gonzalo at the Single Domain Antibodies Meeting 2023 in Paris on his generic #CRISPR #CAR T cell platform! Important tool to improve #cellular #cancer #immunotherapies Rheinische Friedrich-Wilhelms-UniversitĂ€t Bonnâ© âŠImmunoSensationâ© âŠ@MSSOabcdâ© âŠIEO_GloddeLabâ©


In three Phase III trials (mUC: IMvigor211, mRCC: IMmotion151, NSCLC: OAK) immunotherapy prolonged OS when baseline serum albumin was >35g/L -> Prediction of less immune fitness via simple albumin measurement?onlinelibrary.wiley.com/doi/10.1002/ct⊠OncoAlert Clinical & Translational Immunology Tobias Bald IEO_Bonn